



**Food and Drug Administration Advisory Committee Member  
Acknowledgment of Financial Interests**

Name of Advisory Committee Member: Jeffrey M. Feldman, M.D., M.S.E.

Committee: Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee

Meeting Date: February 2, 2024

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the agenda items: The committee will discuss ongoing concerns that pulse oximeters may be less accurate in individuals with darker skin pigmentation. The committee will also discuss an approach to improve the quality of premarket studies and associated methods used to evaluate the performance of pulse oximeters submitted for premarket review, taking into consideration a patient’s skin pigmentation, and patient-reported race and ethnicity, I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
<b>I. Personal/Immediate Family</b>		
Stock/investment	Financial interest in a health sciences sector fund	Value is between \$75,000 - \$125,000
<b>II. Other Imputed Interests</b>		
Employer’s Grant	Federal Grant	Amount awarded between \$250,000 – \$600,000 annually

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

\_\_\_\_\_  
/S/  
Signature

**January 2, 2024**  
\_\_\_\_\_  
Date